Celcuity Inc. CELC
Set alert
At close · Oct 30
After hours · Oct 30, 4:09 PM ET
- YTD
- -30.69%
- 1 year
- -12.45%
- Open
- 68.47
- Prev close
- 69.30
- Mkt cap
- 3.38B
- Vol
- 700.08K
- Avg vol
- 1.18M
- EPS
- -4.31
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 67.42
- High
- 70.43
- Forward P/E
- -864.13
- Beta
- 0.11
- Short ratio
- 7.39
- Inst. own
- 112.68%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 5, 2026
- 50-d avg
- 78.10
- 200-d avg
- 100.86
- 1y target
- 154.72
5D chart
Signals (89)
| Name | Time | Ago |
|---|---|---|
| SMA: Bearish | Oct 30, 9:40 AM | 1 day ago |
| SMA: Bullish | Oct 30, 9:35 AM | 1 day ago |
| SMA: Bullish | Oct 30, 9:35 AM | 1 day ago |
| MACD: Buy Signal | Oct 30, 9:35 AM | 1 day ago |
| MACD: Sell Signal | Oct 30, 9:30 AM | 1 day ago |
| SMA: Bearish | Oct 29, 3:55 PM | 2 days ago |
| SMA: Bullish | Oct 29, 3:50 PM | 2 days ago |
| SMA: Bearish | Oct 29, 3:40 PM | 2 days ago |
| SMA: Bullish | Oct 29, 3:25 PM | 2 days ago |
| MACD: Buy Signal | Oct 29, 2:35 PM | 2 days ago |
| MACD: Sell Signal | Oct 29, 2:15 PM | 2 days ago |
| RSI: Oversold | Oct 29, 2:10 PM | 2 days ago |
| MACD: Buy Signal | Oct 29, 2:05 PM | 2 days ago |
| RSI: Oversold | Oct 29, 1:45 PM | 2 days ago |
| SMA: Bearish | Oct 29, 11:30 AM | 2 days ago |
| SMA: Bearish | Oct 29, 11:25 AM | 2 days ago |
| SMA: Bullish | Oct 29, 11:20 AM | 2 days ago |
| MACD: Sell Signal | Oct 29, 10:35 AM | 2 days ago |
| SMA: Bearish | Oct 29, 10:25 AM | 2 days ago |
| RSI: Overbought | Oct 29, 10:20 AM | 2 days ago |
| SMA: Bullish | Oct 29, 10:15 AM | 2 days ago |
| SMA: Bearish | Oct 29, 10:10 AM | 2 days ago |
| RSI: Overbought | Oct 29, 9:30 AM | 2 days ago |
| MACD: Buy Signal | Oct 28, 4:00 PM | 3 days ago |
| SMA: Bullish | Oct 28, 3:35 PM | 3 days ago |
| SMA: Bullish | Oct 28, 3:30 PM | 3 days ago |
| SMA: Bearish | Oct 28, 3:20 PM | 3 days ago |
| MACD: Sell Signal | Oct 28, 3:20 PM | 3 days ago |
| SMA: Bearish | Oct 28, 3:15 PM | 3 days ago |
| RSI: Overbought | Oct 28, 2:45 PM | 3 days ago |
| SMA: Bullish | Oct 28, 2:25 PM | 3 days ago |
| SMA: Bearish | Oct 28, 2:20 PM | 3 days ago |
| SMA: Bearish | Oct 28, 1:45 PM | 3 days ago |
| SMA: Bullish | Oct 28, 1:15 PM | 3 days ago |
| MACD: Buy Signal | Oct 28, 1:00 PM | 3 days ago |
| SMA: Bullish | Oct 28, 12:50 PM | 3 days ago |
| SMA: Bearish | Oct 28, 12:05 PM | 3 days ago |
| MACD: Sell Signal | Oct 28, 11:35 AM | 3 days ago |
| SMA: Bearish | Oct 28, 11:30 AM | 3 days ago |
| SMA: Bullish | Oct 28, 10:25 AM | 3 days ago |
| SMA: Bearish | Oct 28, 10:20 AM | 3 days ago |
| MACD: Buy Signal | Oct 28, 10:05 AM | 3 days ago |
| SMA: Bullish | Oct 28, 9:50 AM | 3 days ago |
| SMA: Bullish | Oct 28, 9:50 AM | 3 days ago |
| SMA: Bearish | Oct 28, 9:35 AM | 3 days ago |
| SMA: Bullish | Oct 28, 9:30 AM | 3 days ago |
| SMA: Bearish | Oct 27, 3:55 PM | 4 days ago |
| SMA: Bearish | Oct 27, 3:35 PM | 4 days ago |
| MACD: Sell Signal | Oct 27, 3:35 PM | 4 days ago |
| RSI: Overbought | Oct 27, 3:05 PM | 4 days ago |
| RSI: Overbought | Oct 27, 2:45 PM | 4 days ago |
| RSI: Overbought | Oct 27, 2:35 PM | 4 days ago |
| SMA: Bullish | Oct 27, 1:50 PM | 4 days ago |
| SMA: Bearish | Oct 27, 1:40 PM | 4 days ago |
| SMA: Bullish | Oct 27, 1:35 PM | 4 days ago |
| MACD: Buy Signal | Oct 27, 1:35 PM | 4 days ago |
| SMA: Bearish | Oct 27, 1:30 PM | 4 days ago |
| SMA: Bullish | Oct 27, 1:25 PM | 4 days ago |
| SMA: Bullish | Oct 27, 1:20 PM | 4 days ago |
| SMA: Bearish | Oct 27, 12:40 PM | 4 days ago |
| SMA: Bearish | Oct 27, 12:30 PM | 4 days ago |
| SMA: Bullish | Oct 27, 12:10 PM | 4 days ago |
| SMA: Bearish | Oct 27, 12:00 PM | 4 days ago |
| SMA: Bullish | Oct 27, 11:35 AM | 4 days ago |
| SMA: Bearish | Oct 27, 11:30 AM | 4 days ago |
| MACD: Sell Signal | Oct 27, 11:30 AM | 4 days ago |
| RSI: Overbought | Oct 27, 10:55 AM | 4 days ago |
| SMA: Bullish | Oct 27, 10:30 AM | 4 days ago |
| SMA: Bearish | Oct 27, 10:15 AM | 4 days ago |
| RSI: Overbought | Oct 27, 9:40 AM | 4 days ago |
| SMA: Bullish | Oct 27, 9:30 AM | 4 days ago |
| MACD: Buy Signal | Oct 26, 3:30 PM | 5 days ago |
| SMA: Bullish | Oct 26, 3:25 PM | 5 days ago |
| RSI: Oversold | Oct 26, 3:20 PM | 5 days ago |
| RSI: Oversold | Oct 26, 2:30 PM | 5 days ago |
| SMA: Bearish | Oct 26, 2:20 PM | 5 days ago |
| MACD: Sell Signal | Oct 26, 2:20 PM | 5 days ago |
| RSI: Oversold | Oct 26, 2:20 PM | 5 days ago |
| MACD: Buy Signal | Oct 26, 2:10 PM | 5 days ago |
| SMA: Bullish | Oct 26, 2:05 PM | 5 days ago |
| SMA: Bearish | Oct 26, 12:40 PM | 5 days ago |
| MACD: Sell Signal | Oct 26, 12:30 PM | 5 days ago |
| SMA: Bearish | Oct 26, 12:20 PM | 5 days ago |
| SMA: Bullish | Oct 26, 11:35 AM | 5 days ago |
| SMA: Bearish | Oct 26, 11:30 AM | 5 days ago |
| SMA: Bullish | Oct 26, 11:00 AM | 5 days ago |
| SMA: Bearish | Oct 26, 10:55 AM | 5 days ago |
| SMA: Bullish | Oct 26, 10:50 AM | 5 days ago |
| SMA: Bearish | Oct 26, 10:30 AM | 5 days ago |
News
1 day ago seekingalpha.com
Celcuity: Stronger Clinical Evidence, Much Lower Valuation
Celcuity Inc. retains a Buy rating after REVTORPYK's FDA approval and robust mutant data, despite a significant share price drop. REVTORPYK demonstrated strong efficacy and safety, especially versus…
2 days ago globenewswire.com
Celcuity Schedules Release of Third Quarter 2026 Financial Results and Webcast/Conference Call
MINNEAPOLIS, Oct. 29, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a commercial-stage biotechnology company focused on developing and commercializing targeted therapies for the treatment of…
1 week ago globenewswire.com
Celcuity Presents Updated Results from the PIK3CA MT Cohort of the Phase 3 VIKTORIA-1 Study in Patients with HR+/HER2- Advanced Breast Cancer at the ESMO Congress 2026
Median PFS was 21.5 months with the gedatolisib triplet and 11.5 months with the gedatolisib doublet versus 9.1 months with alpelisib + fulvestrant in patients who had no liver metastases
1 week ago globenewswire.com
Celcuity Presents Updated Data from a Phase 1b/2 Study Evaluating Gedatolisib Plus Darolutamide in Men with Metastatic Castration-Resistant Prostate Cancer at the ESMO Congress 2026
Median radiographic progression free survival (“rPFS”) was 15.7 months and the six-month rPFS rate (“rPFS6”) was 82.2% in patients who received prior abiraterone
-
1 week ago benzinga.com
Cantor Fitzgerald Initiates Coverage On Celcuity with Overweight Rating, Announces Price Target of $140
Cantor Fitzgerald analyst Li Watsek initiates coverage on Celcuity (NASDAQ:CELC) with a Overweight rating and announces Price Target of $140.
2 weeks ago zacks.com
New Strong Sell Stocks for October 14th
ADDYY, CELC and CNL have been added to the Zacks Rank #5 (Strong Sell) List on October 14, 2026.
3 weeks ago globenewswire.com
Celcuity Announces Multiple Presentations At The European Society For Medical Oncology (ESMO) Congress 2026
Rapid oral presentation of additional sub-group analyses from the VIKTORIA-1 PIK3CA mutant-type cohort Poster presentation of a comparative analysis of data for the gedatolisib triplet from the…
4 weeks ago globenewswire.com
Celcuity Appoints David Gryska To Its Board Of Directors
Mr. Gryska brings decades of strategic and financial leadership experience to Celcuity's Board Mr. Gryska brings decades of strategic and financial leadership experience to Celcuity's Board
4 weeks ago defenseworld.net
Celcuity (NASDAQ:CELC) Shares Gap Up – Time to Buy?
Celcuity, Inc. (NASDAQ: CELC - Get Free Report)'s share price gapped up prior to trading on Wednesday. The stock had previously closed at $77.38, but opened at $81.30. Celcuity shares last traded at…
1 month ago fool.com
Why Celcuity Stock Was a Winner on Wednesday
This is a breast cancer treatment, Revtorpyk. It was approved by the FDA in July.
-
1 month ago benzinga.com
Needham Maintains Buy on Celcuity, Lowers Price Target to $134
Needham analyst Gil Blum maintains Celcuity (NASDAQ:CELC) with a Buy and lowers the price target from $140 to $134.
-
1 month ago benzinga.com
Celcuity Announces Commercial Availability Of REVTORPYK In U.S. For People With Hormone Receptor-Positive
Celcuity Inc. (Nasdaq: CELC), a biotechnology company focused on developing and commercializing targeted therapies for the treatment of multiple solid tumor indications, today announced that…
1 month ago globenewswire.com
Celcuity Announces That REVTORPYK™ (gedatolisib) Is Now Commercially Available In The United States
REVTORPYK is indicated for patients with HR+/HER2- advanced breast cancer without a PIK3CA mutation detected following progression on or after at least one line of endocrine therapy in the metastatic…
-
1 month ago benzinga.com
JP Morgan Initiates Coverage On Celcuity with Overweight Rating, Announces Price Target of $157
JP Morgan analyst Anupam Rama initiates coverage on Celcuity (NASDAQ:CELC) with a Overweight rating and announces Price Target of $157.
1 month ago benzinga.com
10 Health Care Stocks With Whale Alerts In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
1 month ago seekingalpha.com
Celcuity Inc. (CELC) Presents at Citigroup's Biopharma Back to School Summit 2026 Prepared Remarks Transcript
Celcuity Inc. (CELC) Presents at Citigroup's Biopharma Back to School Summit 2026 Prepared Remarks Transcript
2 months ago globenewswire.com
Celcuity To Participate in Upcoming Investor Conferences
MINNEAPOLIS, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a biotechnology company focused on developing and commercializing targeted therapies for the treatment of multiple solid…
-
2 months ago benzinga.com
Celcuity Files Supplemental New Drug Application To FDA For REVTORPYK To Treat Breast Cancer
Celcuity Inc. (Nasdaq: CELC), a biotechnology company focused on developing and commercializing targeted therapies for multiple solid tumor indications, today announced the submission of its…
2 months ago globenewswire.com
Celcuity Submits sNDA to FDA for REVTORPYK™ (gedatolisib) for HR+/HER2-, PIK3CA Mutant Locally Advanced or Metastatic Breast Cancer
MINNEAPOLIS, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a biotechnology company focused on developing and commercializing targeted therapies for multiple solid tumor indications,…
2 months ago defenseworld.net
Brandywine Managers LLC Acquires New Stake in Celcuity, Inc. $CELC
Brandywine Managers LLC acquired a new stake in shares of Celcuity, Inc. (NASDAQ: CELC) in the second quarter, according to the company in its most recent filing with the Securities and Exchange…
-
2 months ago benzinga.com
Guggenheim Maintains Buy on Celcuity, Raises Price Target to $175
Guggenheim analyst Brad Canino maintains Celcuity (NASDAQ:CELC) with a Buy and raises the price target from $165 to $175.
-
2 months ago benzinga.com
Citizens Reiterates Market Outperform on Celcuity, Maintains $177 Price Target
Citizens analyst Silvan Turkcan reiterates Celcuity (NASDAQ:CELC) with a Market Outperform and maintains $177 price target.
-
2 months ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Celcuity, Maintains $155 Price Target
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Celcuity (NASDAQ:CELC) with a Buy and maintains $155 price target.
2 months ago seekingalpha.com
Celcuity: REVTORPYK Is Now A Commercial Story
Celcuity Inc. remains a Buy as the REVTORPYK/gedatolisib FDA approval and rapid NCCN Category 1 inclusion de-risk clinical and commercial adoption. CELC's financials reflect a front-loaded commercial…
2 months ago benzinga.com
Celcuity Analysts Slash Their Forecasts After Q2 Loss
Celcuity Inc (NASDAQ:CELC) reported a narrower-than-expected loss for the second quarter on Thursday.
2 months ago benzinga.com
Celcuity Analysts Slash Their Forecasts After Q2 Loss
Celcuity Inc (NASDAQ:CELC) reported better-than-expected Q2 losses of $1.07 per share. Analysts are optimistic with price target cuts by Needham and Stifel.
-
2 months ago benzinga.com
Stifel Maintains Buy on Celcuity, Lowers Price Target to $150
Stifel analyst Stephen Willey maintains Celcuity (NASDAQ:CELC) with a Buy and lowers the price target from $175 to $150.
-
2 months ago benzinga.com
Needham Maintains Buy on Celcuity, Lowers Price Target to $140
Needham analyst Gil Blum maintains Celcuity (NASDAQ:CELC) with a Buy and lowers the price target from $157 to $140.
2 months ago seekingalpha.com
Celcuity Inc. (CELC) Q2 2026 Earnings Call Transcript
Celcuity Inc. (CELC) Q2 2026 Earnings Call Transcript
2 months ago marketbeat.com
Celcuity Q2 Earnings Call Highlights
Celcuity NASDAQ: CELC said it remains on track to begin commercial shipments of REVTORPYK, its gedatolisib therapy for certain patients with advanced breast cancer, late in the third quarter of 2026…
2 months ago benzinga.com
Celcuity Reports Q2 2026 Results: Full Earnings Call Transcript
On Thursday, Celcuity (NASDAQ:CELC) discussed second-quarter financial results during its earnings call. The full transcript is provided below. Benzinga APIs provide real-time access to earnings call…
-
2 months ago benzinga.com
Celcuity Q2 Adj. EPS $(1.07) Beats $(1.17) Estimate
Celcuity (NASDAQ:CELC) reported quarterly losses of $(1.07) per share which beat the analyst consensus estimate of $(1.17) by 7.76 percent. This is a 15.05 percent decrease over losses of $(0.93) per…
2 months ago globenewswire.com
Celcuity Inc. Reports Release of Second Quarter 2026 Financial Results and Provides Corporate Update
MINNEAPOLIS, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a biotechnology company focused on developing and commercializing targeted therapies for the treatment of multiple solid…
2 months ago defenseworld.net
California State Teachers Retirement System Acquires 12,201 Shares of Celcuity, Inc. $CELC
California State Teachers Retirement System lifted its holdings in Celcuity, Inc. (NASDAQ: CELC) by 91.2% in the first quarter, according to its most recent disclosure with the Securities and…
-
3 months ago benzinga.com
Celcuity's REVTORPYK Receives Recommendation From National Comprehensive Cancer Network Clinical Practice Guidelines In Oncology As Preferred Category 1 Second-Line Therapy
Celcuity Inc. (Nasdaq: CELC), a biotechnology company focused on developing and commercializing targeted therapies for multiple solid tumor indications, today announced that REVTORPYK™ (gedatolisib)…
3 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers China Pharma Holding (AMEX:CPHI) shares moved upwards by 67.6% to $1.03 during Wednesday's regular session. The market value of their outstanding shares is at $24.9 million. Conexeu Sciences…
-
3 months ago benzinga.com
Citizens Maintains Market Outperform on Celcuity, Raises Price Target to $177
Citizens analyst Silvan Turkcan maintains Celcuity (NASDAQ:CELC) with a Market Outperform and raises the price target from $160 to $177.
3 months ago benzinga.com
CrowdStrike To Rally Over 12%? Here Are 10 Top Analyst Forecasts For Wednesday
Top Wall Street analysts changed outlook on top names. See all changes, including upgrades/downgrades, on our analyst ratings page.
-
3 months ago benzinga.com
HC Wainwright & Co. Maintains Buy on Celcuity, Raises Price Target to $155
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Celcuity (NASDAQ:CELC) with a Buy and raises the price target from $145 to $155.
5 months ago benzinga.com
Palo Alto Networks To Rally Nearly 70%? Here Are 10 Notable Analyst Calls From Wednesday
Top Wall Street analysts changed outlook on top names. For all rating changes, upgrades and downgrades, visit analyst ratings page.
5 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Intraday Session
12 Health Care Stocks Moving In Tuesday's Intraday Session
6 months ago benzinga.com
Global Business Travel Group Posts Upbeat Q1 Results, Joins Cabaletta Bio, Aura Biosciences And Other Big Stocks Moving Higher On Monday
Global Business Travel Group Inc (GBTG), a NYSE-listed company, saw its stock rise 57% on Monday after reporting better-than-expected financial results. Other top gainers included companies like…
6 months ago benzinga.com
This Prudential Financial Analyst Turns Bearish; Here Are Top 5 Downgrades For Monday
Wall Street analysts changed outlook on top names, including PRU, ARE, TRGP, VITL, and GOOGL. See analyst ratings page for more info.
-
6 months ago benzinga.com
12 Health Care Stocks Moving In Monday's Pre-Market Session
12 Health Care Stocks Moving In Monday's Pre-Market Session
6 months ago benzinga.com
This First Tracks Biotherapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Monday
Top Wall Street analysts changed outlook on top stocks. See analyst ratings page for changes, including upgrades, downgrades, and initiations.
6 months ago benzinga.com
This Airbnb Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday
Wall Street analysts upgraded and raised price targets for ESS, SITE, PKG, ABNB, and CELC. See what other analysts think before buying ABNB stock.
6 months ago benzinga.com
Packaging Corp Of America To Rally More Than 17%? Here Are 10 Top Analyst Forecasts For Monday
Needham analyst Rick Patel maintained a Buy rating. Steven Madden shares closed at $47.27 on Friday. Top analysts change outlook on BTSG, CELC, ESS, CORT, PKG, PRU, RVTY, and SHOO. See how they rate…
6 months ago benzinga.com
Why eBay Shares Are Trading Higher By 8%; Here Are 20 Stocks Moving Premarket
eBay (NASDAQ: EBAY) rose sharply after GameStop (NYSE: GME) proposed to acquire it for $125/share, valuing GME at $55.5B. eBay shares jumped 8.1% to $112.50 in pre-market trading.
-
7 months ago benzinga.com
Earnings Scheduled For March 25, 2026
Earnings Scheduled For March 25, 2026